EXHIBIT 10.28
TERMINATION OF DEVELOPMENT SUPPLY AGREEMENT AND
PURCHASE/SUPPLY AGREEMENT
THIS TERMINATION AGREEMENT (the "Agreement") is made and entered into
as of December 6, 2002, by and between INTRABIOTICS PHARMACEUTICALS, INC.,
("IntraBiotics"), a Delaware corporation having its principal place of business
at 0000 Xxxxx Xxxxx Xxxxxx, Xxxxxxxx Xxxx, XX 00000 and POLYPEPTIDE LABORATORIES
A/S, a corporation incorporated under the laws of Denmark ("Polypeptide
Laboratories") with its registered offices at Xxxxxxxxxxxx 0, 0000 Xxxxxx0x,
Xxxxxxx, and POLYPEPTIDE LABORATORIES AB, a corporation incorporated under the
laws of Sweden, with its registered offices at Xxxxxxxxxxxxx 00, X.X. Xxx 00000,
XX-000 00 Xxxxxxx, Xxxxxx (collectively, "Polypeptide"). IntraBiotics and
Polypeptide may be referred to herein as a "Party" or, collectively, as
"Parties".
RECITALS
WHEREAS, IntraBiotics and Polypeptide entered into a Development Supply
Agreement, dated January 3, 1997 (the "Development Agreement"), pursuant to
which Polypeptide agreed to develop, manufacture and supply IntraBiotics with
quantities of IntraBiotics' proprietary peptide, IB-367 ("Product") in bulk
form, and a Purchase/Supply Agreement, dated January 3, 1997 (the "Purchase
Agreement"), pursuant to which Polypeptide agreed to manufacture and supply to
IntraBiotics commercial quantities of Product in bulk form;
WHEREAS, in the course of such relationship, IntraBiotics ordered five
lots of Product (lots H, I, J, K and L) from Polypeptide by letter dated
September 5, 2000 (the "September 2000 Order"), of which lots H and I are being
manufactured in sublots as follows: X-0, X-0, X-0, X-0, X-0, I-2 and I-3;
WHEREAS, Polypeptide has recently completed manufacture of Product lots
H1-H4, expects to complete manufacture of Product lots I1-3 in the near future,
and, at IntraBiotics' request, has ceased manufacturing activities with respect
to Product lots J, K and L ordered by IntraBiotics, which lots are in various
states of partial manufacture;
WHEREAS, IntraBiotics and Polypeptide now desire to wind up their
business relationship with respect to Product, cancel the September 2000 Order,
extinguish the Standby Letters of Credit Nos. SVB01IS3761 and SVB01IS3762
securing the September 2000 Order, and provide for delivery and storage of the
completed lots and the fragments and intermediates of the remaining lots until
such time as IntraBiotics is ready to receive such completed lots, fragments and
intermediates; and
NOW THEREFORE, in consideration of the covenants and promises set forth
herein, and for other valuable consideration, the Parties agree as follows:
AGREEMENT
1.
1. PRODUCT PAYMENTS.
1.1 IntraBiotics shall pay to Polypeptide the following amounts:
(a) $4,703,000, concurrent with the execution of this Agreement; (b) $250,000,
which shall be paid by wire transfer as set forth in Section 1.2, to be
initiated not later than the first business day following the expiration of the
Acceptance Period (as defined in Section 2.2) for sublot I-2; and (c) $40,000,
which shall be paid by wire transfer as set forth in Section 1.2, to be
initiated not later than 15 days after receipt by IntraBiotics of the Completed
Development Report as described in Item 1 of Exhibit C. Payment due on
IntraBiotics' acceptance of sublot I-2 shall be secured by a letter of credit in
substantially the form attached hereto as Exhibit A.
1.2 METHOD OF PAYMENT. All payments due hereunder to Polypeptide
shall be paid to Polypeptide in United States Dollars. Payment shall be made by
wire transfer to:
Danske Bank
Finance Center Copenhagen
Holmens Kanal 2
DK-1090 Copenhagen K
Denmark
Fax x00 000 0000
Swift Code: dabadkkk
Account No: [Account Number]
2. DELIVERY AND ACCEPTANCE OF PRODUCT
2.1 DELIVERY OF PRODUCT. Polypeptide shall deliver each sublot of
Product in accordance with the schedule set forth on Exhibit B, by shipping to
IntraBiotics a two (2) gram sample of such Product, a Certificate of Analysis
for such Product, a statement of GMP compliance, and the following
documentation: (i) copies of the executed batch records for steps 2398, 2403 and
3107, (ii) translated copies of all documentation concerning any manufacturing
process deviations and (iii) the synthesis tree for the corresponding sample of
Product. Such shipment shall be made FCA (Incoterms 2000) Copenhagen. Not later
than December 15, 2002, Polypeptide shall deliver (a) a written inventory of
each Product fragment and intermediate in Polypeptide's custody identifying each
such fragment and intermediate by part number and specifying the quantity
thereof; and (b) copies of the QC release testing and QA disposition
documentation for fragments 2396, 2394, 2392, 2390 and 2386 and intermediates
2401 and 2399. IntraBiotics may examine all original documentation with respect
to such Product fragments and intermediates at Polypeptide's facility, upon
reasonable notice and during normal business hours.
2.2 TESTING AND ACCEPTANCE/REJECTION.
(a) SAMPLES. Polypeptide shall test sublots I-1 through
I-3 for conformance to the specifications as defined in Polypeptide document
3107-02. IntraBiotics shall test all samples delivered pursuant to Section 2.1
for conformity to the specifications as defined in IntraBiotics document
S-2000.3 (the "Specifications"), a copy of which has been delivered to
Polypeptide. IntraBiotics may reject any sample delivery which does not conform
with the
2.
Specifications or with the documentation referred to in Section 2.1. Any such
notice of rejection shall be given in writing within forty-five (45) days after
delivery of such sample and documentation (the "Acceptance Period"), and shall
specify the reasons for such rejection, including a report of analysis or cGMP
deviation of the allegedly non-conforming Product. If no such notice of
rejection is received by Polypeptide within the Acceptance Period, IntraBiotics
shall be deemed to have accepted the relevant Product sublot. Once IntraBiotics
accepts a Product sublot, IntraBiotics shall have no recourse against
Polypeptide if the Product is subsequently deemed unsuitable for use for any
reason, except as provided in Section 4.4 below.
(b) POST-REJECTION PROCEDURE. If notice of rejection is
given, IntraBiotics shall cooperate with Polypeptide in determining whether
rejection is necessary or justified. Polypeptide will evaluate process issues
and other reasons for such non-compliance. Polypeptide shall notify IntraBiotics
as promptly as reasonably possible whether it accepts IntraBiotics' basis for
any rejection. If Polypeptide disagrees with IntraBiotics' determination that
certain Product does not meet the Specifications or the documentation referred
to in Section 2.1, such Product shall be submitted to a mutually acceptable
third party laboratory or consultant (the "Laboratory/Consultant"). Such
Laboratory/Consultant shall determine whether such Product meets the
Specifications and such documentation and the parties agree that such
Laboratory's/Consultant's determination shall be final and determinative. The
party against whom the Laboratory/Consultant rules shall bear all costs of the
Laboratory/Consultant testing/consultation. If the Laboratory/Consultant rules
that the Product meets Specifications and such documentation, IntraBiotics shall
pay the amount due under Section 1.1 (b) for such sublot. If the
Laboratory/Consultant rules that the sublot does not meet Specifications or such
documentation, IntraBiotics shall not be obligated to make any further payment
under Section 1.1 above, subject to the following sentence. In such event,
Polypeptide may reprocess the material and resubmit it to IntraBiotics for
approval, and such resubmitted material shall again be subject to the
approval/rejection procedure and schedule set forth in this Section 2.2.
2.3 PRODUCT RELEASE. Upon receipt of written notice from
IntraBiotics that a delivery of Product has been accepted, or upon expiration of
the Acceptance Period without notice from IntraBiotics, Polypeptide shall
release the relevant Product sublot to the Storage Site (as defined in Section
4.1), and IntraBiotics shall make any payment due pursuant to Section 1.1. The
quantities of Product set forth in Exhibit B for each sublot represent
Polypeptide's best estimates of the allocation of Product among sublots.
IntraBiotics acknowledges that actual release quantities may vary among sublots;
however, Polypeptide shall be obligated to release to storage the total quantity
of Product for Lot I set forth in Exhibit B. Upon delivery to IntraBiotics of
the documentation described in Section 2.1 relating to fragments and
intermediates, Polypeptide shall release the fragments and intermediates to the
Storage Site.
3. OTHER DELIVERABLES AND DOCUMENT RETENTION.
3.1 OTHER DELIVERABLES. Polypeptide shall deliver to IntraBiotics
the items specified on Exhibit C in accordance with the schedule set forth
thereon.
3.2 DOCUMENT RETENTION. Polypeptide shall retain the original
documents identified on Exhibit D for a period of not less than 5 years from the
Effective Date, and shall not destroy any such records at any time without
thirty (30) days written notice to IntraBiotics.
3.
4. STORAGE OF PRODUCT.
4.1 STORAGE. Polypeptide shall store Product lots H and I, and the
fragments and intermediates of lots J, K and L, in accordance with the storage
conditions specified in Section 4.4 below, at Polypeptide's facility at
Hillerod, Denmark (the "Storage Site"). Alternatively, Polypeptide may store
such Product in accordance with the storage conditions specified in Section 4.4
below, at Polypeptide's facility in Malmo, Sweden or such other facility as
Polypeptide may propose, provided that Polypeptide shall so notify IntraBiotics
in writing at least 30 days prior to moving the Product, and shall include in
such notice the information specified in Exhibit E. IntraBiotics may object to
such relocation of the Product, in writing, not later than 10 days prior to the
proposed moving date. In such event, the Parties shall confer in good faith as
to the reasons for the proposed relocation and IntraBiotic's objections, and
shall discuss appropriate mechanisms to address both Parties' objectives and
concerns, and Polypeptide shall not move the Product until such dispute is
resolved. Storage of each Product sublot shall commence upon IntraBiotics'
acceptance of such sublot pursuant to Article 2. Storage of the fragments and
intermediates of Product lots J, K and L shall commence upon Polypeptide's
release of such fragments and intermediates pursuant to Article 2. Title and
risk of loss for each sublot, fragment and intermediate of Product that is
stored by Polypeptide shall transfer from Polypeptide to IntraBiotics
immediately upon the commencement of the applicable Storage Period (as defined
in Section 4.3). IntraBiotics shall be responsible for obtaining and maintaining
appropriate insurance for such stored Product, and Polypeptide shall cooperate
with IntraBiotics' attempts to acquire such insurance.
4.2 STORAGE FEE. Polypeptide shall store the Product for the
duration of the Storage Period (as defined in Section 4.3) at a total cost to
IntraBiotics of $250,000, payable at a rate of $12,500 per calendar quarter of
the Storage Period. The initial Storage Fee payment shall be due concurrent with
the execution of this Agreement, and shall be prorated based on the date of such
execution. Thereafter Polypeptide shall submit an invoice to IntraBiotics for
the quarterly Storage Fee payments on the first day of each subsequent calendar
quarter of the Storage Period. IntraBiotics' payment thereon shall be due not
later than 30 days after receipt of such invoice, and shall be paid in
accordance with Section 1.2.
4.3 TERM OF STORAGE. Polypeptide shall store the Product for up to
five years from the date the first sublot of Product commences storage (the
"Storage Period"). If IntraBiotics wishes to terminate the storage arrangements
prior to the expiration of the Storage Period, it shall notify Polypeptide in
writing at least 30 days prior to the date such termination is to be effective
(the "Storage Termination Notice"), and shall provide written instructions as to
the disposition of the stored and any unreleased Product. Polypeptide shall ship
all such Product FCA (Incoterms 2000) Copenhagen to the location specified by
IntraBiotics, not later than the effective date of termination. Any unpaid
balance on the Storage Fee shall accelerate on the effective date of such
termination, and IntraBiotics shall pay to Polypeptide the balance due on the
Storage Fee not later than 10 business days after receipt of the entire quantity
of stored and unreleased (if any) Product lots, fragments and intermediates.
4.4 CONDITIONS OF STORAGE. Polypeptide will store lots H1, H2, H3,
H4, I1, I2, and I3 at a temperature of -20 degrees Centigrade, plus or minus 5
degrees Centigrade, and the fragments and intermediates at a temperature lower
than 8 degrees Centigrade. The Product
4.
shall be stored in qualified xxxxxxxx that have continuous monitoring of
temperature in the form of chart recorders or electronic data-logging.
Polypeptide will not be responsible for any degradation of the Product provided
that the Product is stored at -20 degrees Centigrade, plus or minus 5 degrees
Centigrade, and less than 8 degrees Centigrade, respectively, at all times. In
any event, Polypeptide shall not be responsible for any damage to the Product
that occurs by reason of force majeure. As used in this Section 4.4, "qualified
xxxxxxxx" shall mean xxxxxxxx meeting ICH guidelines.
4.5 MONITORING OF STORED PRODUCT. At IntraBiotics request, the
temperature and maintenance logs of the storage xxxxxxxx will be forwarded to
IntraBiotics for review. The power supply to the xxxxxxxx will have generator
backup in case of power failure. Polypeptide will upon written request by
IntraBiotics and not more often than once per year, ship to IntraBiotics or a
designated facility, a sample of each of sublots H1, H2, H3, H4, I1, I2 and I3.
4.6 TERMINATION OF STORAGE.
(a) IntraBiotics may terminate the storage arrangements
that are the subject of this Agreement for any reason or no reason on thirty
(30) days written notice to Polypeptide.
(b) Either party may terminate the storage arrangements
that are the subject of this Agreement upon written notice to the other party if
the other party commits any material breach of this Agreement which the
breaching party fails to cure within ten (10) days as to a failure to pay
amounts owed hereunder, or two (2) days as to a failure to comply with Section
4.4, or thirty (30) days as to any other material breach, following written
notice from the nonbreaching party specifying the relevant breach.
(c) In the event of the termination of the storage
arrangements, any unpaid balance on the Storage Fee shall accelerate as provided
in Section 4.3
5. TERMINATION OF DEVELOPMENT AGREEMENT AND PURCHASE AGREEMENT. Effective
upon the Effective Date of this Agreement, the Development Agreement and the
Purchase Agreement shall each terminate, provided that the following Articles
and Sections shall survive such termination:
DEVELOPMENT AGREEMENT: Articles 5, 9, 10, 11 and 16
PURCHASE AGREEMENT: Articles 8 and 10, and Section 13.7
6. MISCELLANEOUS.
6.1 GOVERNING LAW. This Agreement is made in accordance with and
shall be governed and construed under the laws of the State of California,
excluding its choice of law rules.
6.2 NOTICE. All notices, including notices of address change,
required or permitted to be given under this Agreement shall be in writing and
deemed to have been received (a) when received if hand delivered, (b) one (1)
business day after being sent by overnight courier, or (c)
5.
when received if sent by confirmed telecopy, in each case addressed to the
address set forth below:
IntraBiotics:
IntraBiotics Pharmaceuticals, Inc.
0000 Xxxxx Xxxxx Xxxxxx
Xxxxxxxx Xxxx, XX 00000
Attn: Xxxx Xxxxxxxxx, CFO
(000) 000-0000 (fax)
With a copy to:
Xxxxxx Godward LLP
5 Palo Alto Square
0000 Xx Xxxxxx Xxxx
Xxxx Xxxx, XX 00000
Attn: Xxxxxx X. Xxxxx, Esq.
(000) 000-0000 (fax)
PPL:
Polypeptide Laboratories A/S
Xxxxxxxxxxxx 0
XX- 0000 Xxxxxxxx
Xxxxxxx
Attn: Managing Director
x00-00000000 (fax)
With a copy to:
Xxxxxx Xxxxx, Esq.
Suite 300
000 Xxxxx Xxxxxxxxx
Xxxxxxx, XX 00000
000-000-0000 (fax)
6.3 SEVERABILITY. In the event any provision of this Agreement is
held to be invalid or unenforceable, the valid or enforceable portion thereof
and the remaining provisions of this Agreement will remain in full force and
effect.
6.4 WAIVER. Any waiver (express or implied) by either party of any
breach of this Agreement shall not constitute a waiver of any other or
subsequent breach.
6.5 ENTIRE AGREEMENT. This Agreement and the exhibits attached
hereto, constitute the entire, final, complete and exclusive agreement between
the parties and supersede all
6.
previous agreements or representations, written or oral, with respect to the
subject matter of this Agreement.
6.6 MODIFICATIONS. This Agreement and its terms, including but not
limited to performance obligations hereunder, may not be modified or amended
except in a writing signed by a duly authorized representative of each party.
6.7 NONASSIGNABILITY; BINDING ON SUCCESSORS. Except to an
Affiliate or in connection with any sale of all or substantially all of either
party's assets, whether by merger or otherwise, any attempted assignment of the
rights or delegation of the obligations under this Agreement shall be void
without the prior written consent of the nonassigning or nondelegating party. In
the case of any permitted assignment or transfer of or under this Agreement,
this Agreement shall be binding upon, and inure to the benefit of, the
successors, executors, heirs, representatives, administrators and assigns of the
parties hereto.
6.8 FORCE MAJEURE. Neither party shall be liable to the other for
its failure to perform any of its obligations under this Agreement during any
period in which such performance is delayed because rendered impracticable or
impossible due to circumstances beyond its reasonable control, including without
limitation earthquakes, governmental regulation, fire, flood, labor
difficulties, civil disorder, and acts of God, provided that the party
experiencing the delay promptly notifies the other party of the delay, and
provided further that if such delay exceeds 2 days, IntraBiotics may at its
discretion seek storage services from a Third Party, in which event any unpaid
balance on the Storage Fee shall accelerate as provided in Section 4.3.
6.9 CANCELLATION OF LETTERS OF CREDIT. Polypeptide hereby consents
to the cancellation of Standby Letters of Credit Nos. SVB01IS3761 and
SVB01IS3762 on or after the Effective Date of this Agreement, as IntraBiotics
shall elect.
6.10 COUNTERPARTS; FACSIMILE. This Agreement may be executed in two
(2) or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one (1) and the same instrument, and by
facsimile.
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
Effective Date.
INTRABIOTICS PHARMACEUTICALS, INC. POLYPEPTIDE LABORATORIES A/S
/s/ Xxxx Xxxxxxxxx /s/ Xxxx Xxxxxxxxx
------------------------ ----------------------------------
Xxxx Xxxxxxxxx
POLYPEPTIDE LABORATORIES AB
/s/ Xxxx Xxxxxxxxx
---------------------------------
Xxxx Xxxxxxxxx
7.
EXHIBIT A
FORM OF LETTER OF CREDIT
1.
From: XXXXXX0X SWIFT MESSAGE
SILICON VALLEY BANK
0000 XXXXXX XXXXX
XXXXX XXXXX, XX 00000
To: UNIBDKKK DRAFT NUMBER 1.
UNIBANK A/S
COPENHAGEN
DENMARK
Date: 0212___
MT700: ISSUE OF A STANDBY LETTER OF CREDIT
:27 Sequence of Total: 1/1
:40A Form of Documentary Credit: IRREVOCABLE STANDBY
:20 Documentary Credit Number: SVBSF ___
..31C Date of Issue: 0212__
:31D Date and place of expiry: 000000 XX XXXXX XXXXX, XX
:50 Applicant: INTRABIOTICS PHARMACEUTICALS, INC.
0000 XXXXX XXXXX XXXXXX
XXXXXXXX XXXX, XX 00000
:59 Beneficiary: POLYPEPTIDE XXXXXXXXXXXX X/X
XXXXXXXXXXXXX 0
XX-0000 XXXXXXXX
XXXXXXX
:32B Currency Code. Amount: USD250.000,00
:41A Available With . . . By . . .: XXXXXX0X
BY PAYMENT
:42C Draft at . . . SIGHT
:42a Drawee XXXXXX0X
:46A Documents required:
1. BENEFICIARY'S DATED STATEMENT SIGNED BY AN AUTHORIZED
REPRESENTATIVE OF THE BENEFICIARY AS FOLLOWS: "IT IS HEREBY
CERTIFIED THAT (1) THE SIGNATORY HERETO IS AN AUTHORIZED SIGNER OF
BENEFICIARY; AND (II) INTRABIOTICS PHARMACEUTICALS, INC. FAILED TO
PAY THE AMOUNT DUE UNDER SECTION 1.1(b) OF THE AGREEMENT ENTITLED
'TERMINATION OF DEVELOPMENT SUPPLY AGREEMENT AND PURCHASE/SUPPLY
AGREEMENT' DATED DECEMBER 6,2002 ("TERMINATION
2.
AGREEMENT") WITHIN THE TIME PERMITTED UNDER THE TERMINATION
AGREEMENT OR OTHERWISE CONSISTENT WITHIN PAYMENT PROVISIONS.
POLYPEPTIDE LABORATORIES A/S THEREFORE DEMANDS PAYMENT OF THE SUM
USD (INSERT AMOUNT UP TO FULL AVAILABLE AMOUNT OF THE LETTER OF
CREDIT
:47A Additional Conditions:
+THIS LETTER OF CREDIT IS NON-OPERATIVE. WE WILL MAKE THIS LETTER OF
CREDIT OPERATIVE WHEN WE RECEIVE AN AUTHENTICATED MT799 FROM UNIBANK
A/S THAT OUR LETTERS OF CREDIT NO. SVB01IS3761 AND SVB01IS3763 HAVE
BEEN RETURNED TO THEM FOR CANCELLATION.
+ ALL DOCUMENTS ISSUED MUST READ IN THE ENGLISH LANGUAGE AND INDICATE
OUR LETTER OF CREDIT NUMBER.
+ NEGOTIATING BANK MUST TELEX ADVISE US WITHIN 24 HOURS FROM THE DATE
OF NEGOTIATION INDICATING THE DRAWING AMOUNT.
+ A DISCREPANCY CHARGE OF USD55.00 FOR BENEFICIARY'S ACCOUNT
WILL BE ASSESSED BY US FOR EACH SET OF DOCUMENTS UNDER SUBJECT LETTER
OF CREDIT, WHICH CONTAINS DISCREPANCIES.
:71B Charges: ALL CHARGES ARE FOR ACCOUNT OF THE APPLICANT
:49 Confirmation Instructions: WITHOUT
:78 Instructions to the Paying/Accepting/Negotiating Bank:
+ DOCUMENTS MUST BE FORWARDED DIRECTLY TO US BY COURIER SERVICE AT:
SILICON VALLEY BANK, 3003 TASMAN DRIVE, MAIL SORT HF210, ATTN:
INTERNATIONAL DEPARTMENT, XXXXX XXXXX, XX 00000 XXX
+UPON RECEIPT OF CONFORMING DOCUMENTS WE WILL REMIT PAYMENT IN
ACCORDANCE WITH INSTRUCTIONS RECEIVED.
:72 Sender to Receiver Information:
3.
EXHIBIT B
DELIVERY SCHEDULE
=======================================================
ESTIMATED DELIVERY
SUB-LOT QUANTITY (WEEK COMMENCING)
=======================================================
I-1 Variable 17 Feb 03
-------------------------------------------------------
I-2 Variable 10 Mar 03
-------------------------------------------------------
I-3 Variable 31 Mar 03
-------------------------------------------------------
Total I 7,000 g
=======================================================
1.
EXHIBIT C
OTHER DELIVERABLES
----------------------------------------------------------------------------------------------------------------------
DELIVERY DATE ITEM
----------------------------------------------------------------------------------------------------------------------
31 Mar 03 1. Completed Development Report for all steps in the
production of Iseganan HCl (including but not limited
to all pertinent data generated to date for all lots (A
- G2-05))
----------------------------------------------------------------------------------------------------------------------
Prior to initiation of step 33107 for sublot I-1. 2. A summary of the pre-validation data for step 33107
----------------------------------------------------------------------------------------------------------------------
Not later than 45 days after delivery of the sublot I-2 3. Completed pre-validation report for step 33107
sample.
----------------------------------------------------------------------------------------------------------------------
1.
EXHIBIT D
DOCUMENTS TO BE RETAINED
The following documents shall be retained in accordance with Section 3.2, to
the extent such documents relate to the Product or any sublots, fragments or
intermediates thereof:
All original Batch records including chromatograms and all ancillary data.
Equipment IQ/OQ/PQ files
Equipment logs (cleaning and use logs as appropriate)
Any equipment cleaning qualification information
All Quality Control results for raw material, in-process and final release of
materials
Training files for personnel who worked on Products (including Product sublots
and Product fragments and intermediates)
Critical Vendor audits (Xxxx, raw material and analytical services contractors)
Method validation files (if relevant)
Deviation and OOS files
Stability studies
A copy of all SOP's and QC methods that were used
All change control documentation
2.
EXHIBIT E
INFORMATION TO BE INCLUDED IN NOTICE OF PROPOSED CHANGE OF STORAGE SITE
1. Street address, city and country of proposed storage site.
2. Telephone number of proposed storage site.
3. Name and telephone number of contact person at proposed storage site.
4. Does Polypeptide own or lease proposed storage site?
5. Area of building:
6. Area occupied by Polypeptide:
7. Are there other occupants of the proposed storage type? If yes,
what type?
8. Who insures building?
9. Describe building construction.
10. Year built:
11. Number of stories:
12. Does building have:
a. Sprinklers?
b. Fire alarm?
c. Burglar alarm?
d. 24 hour guards?
1.
